Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00208143 · ClinicalTrials.gov registry record · Phase 4
Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia
A Phase 4 study, sponsored by Creighton University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00208143 is a Phase 4 study that has completed, run by Creighton University. The registered enrollment target is 20 participants.
The verdict
NCT00208143, a Phase 4 study, has completed, sponsored by Creighton University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
It is hypothesized that the atypical antipsychotic, Seroquel, will cause significant reduction in drug and alcohol cravings in patients with schizophrenia and comorbid cocaine and/methamphetamine dependence compared to the atypical antipsychotic, risperidone (Risperdal). Patients treated with Seroquel will have less use of cocaine and/or methamphetamine as measured by the Time Line Follow-back, over a 24-week follow-up period.
Interventions
- DRUG Risperidone
- DRUG Quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2003-11 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00208143
The ClinicalTrials.gov registry entry for NCT00208143 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Creighton University, which has 98 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Risperidone is the first listed.
NCT00208143 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00208143 about?
NCT00208143 is a clinical study titled "Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia". It is hypothesized that the atypical antipsychotic, Seroquel, will cause significant reduction in drug and alcohol cravings in patients with schizophrenia and comorbid cocaine and/methamphetamine dependence compared to the atypical antipsychotic, risperidone (Risperdal). Patients treated with Seroq...
What is the current status of trial NCT00208143?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2003-11. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00208143?
The interventions under investigation include: Risperidone (DRUG), Quetiapine (DRUG).
Who is sponsoring clinical trial NCT00208143?
This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.